A novel synthesis of oligonucleotide-peptide conjugates with a base- labile phosphate linker between the two components according to the allyl- protected phosphoramidite strategy

Tetrahedron

Volumn 56, Issue 26, 2000, Pages 4427-4435

  Sakakura, Akira ^a   Hayakawa, Yoshihiro ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

Nucleic acid analogs; Peptide analogs; Phosphoramidites; Solid phase synthesis

Indexed keywords

OLIGONUCLEOTIDE; PEPTIDE;

ARTICLE; CHEMICAL REACTION; CONJUGATION; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN SYNTHESIS;

EID: 0034705563     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(00)00376-8     Document Type: Article

References (34)

1. Ratajczak M.Z., Gewirtz A.M. Nucl. Acids Mol. Biol. 8:1994;298-326.
2. Beaucage S.L., Iyer R.P. Tetrahedron. 49:1993;1925-1963.
3. Uhlmann E., Peyman A. Chem. Rev. 90:1990;543-584.
4. Degols G., Leonetti J.-P., Benkirane M., Devaux C., Lebleu B. Antisense Res. Dev. 2:1992;293-301.
5. Stevenson M., Iversen P. J. Gen. Virol. 70:1989;2673-2682.
6. Chaloin L., Vidal P., Méry J., Lautredou N., Divita G., Heitz F. Biochem. Biophys. Res. Commun. 243:1998;601-608.
7. Bongartz J.-P., Aubertin A.-M., Milhaud P.G., Lebleu B. Nucl. Acids Res. 22:1994;4681-4688.
8. Arar K., Aubertin A.-M., Roche A.-C., Monsigny M., Mayer R. Bioconjugate Chem. 6:1995;573-577.
9. Zuckermann R.N., Schultz P.G. J. Am. Chem. Soc. 110:1988;6594-6596.
10. Kitamura N., Semler B.L., Rothberg P.G., Larsen G.R., Adler C.J., Dorner A.J., Emini E.A., Hanecak R., Lee J.J., van der Werf S., Anderson C.W., Wimmer E. Nature. 291:1981;547-553.
11. Stillman B.W. Cell. 35:1983;7-9.
12. Dreef-Tromp C.M., van der Maarel J.M.C., van den Elst H., van der Marel G.A., van Boom J.H. Nucl. Acids Res. 20:1992;4015-4020.
13. Robles J., Maseda M., Beltrán M., Concernau M., Pedroso E., Grandas A. Bioconjugate Chem. 8:1997;785-788.
14. Ueno Y., Saito R., Hata T. Nucl. Acids Res. 21:1993;4451-4457.
15. Truffert J.-C., Asseline U., Brack A., Thuong N.T. Tetrahedron. 52:1996;3005-3016.
16. Soukchareun S., Tregear G.W., Haralambidis J. Bioconjugate Chem. 6:1995;43-53.
17. Basu S., Wickstrom E. Tetrahedron Lett. 36:1995;4943-4946.
18. Vivès E., Lebleu B. Tetrahedron Lett. 38:1997;1183-1186.
19. Arar K., Monsigny M., Mayer R. Tetrahedron Lett. 34:1993;8087-8090.
20. McMinn D.L., Greenberg M.M. Bioorg. Med. Chem. Lett. 9:1999;547-550.
21. Conjugates of type A might be more attractive as chemotherapeutical substances than conjugates of type B, because the digestion produces only biological substances including nucleosides, nucleotides, amino acids, and peptides in the former conjugates, but produces the undesired, non-biological linker or its fragments in the latter conjugates.
22. Part of the results described here have been preliminarily reported in Sakakura, A.; Hayakawa, Y.; Harada, H.; Hirose, M.; Noyori, R. Tetrahedron Lett. 1999, 40, 4359-4362.
23. Hayakawa Y., Kataoka M. J. Am. Chem. Soc. 119:1997;11758-11762.
24. Hayakawa Y., Hirose M., Hayakawa M., Noyori R. J. Org. Chem. 60:1995;925-930.
25. Hayakawa Y., Wakabayashi S., Kato H., Noyori R. J. Am. Chem. Soc. 112:1990;1691-1696.
26. Hayakawa Y., Kataoka M., Noyori R. J. Org. Chem. 61:1996;7996-7997.
27. Heidenhain S.B., Hayakawa Y. Nucleosides Nucleotides. 18:1999;1771-1787.
28. Heidenhain S.B., Hayakawa Y. Synlett. 1998;853-854.
29. Waldmann H., Kunz H. Liebigs Ann. Chem. 1983;1712-1725.
30. Paulsen H., Mertz G., Brockhausen I. Liebigs Ann. Chem. 1990;719-739.
31. Ueda Y., Mikkilineni A., Partyka R.A. Bioorg. Med. Chem. Lett. 2:1992;1541-1546.
32. Castro B., Dormoy J.R., Evin G., Selve C. Tetrahedron Lett. 1975;1219-1222.
33. Hayakawa Y., Uchiyama M., Noyori R. Tetrahedron Lett. 27:1986;4191-4194.
34. Structures of degradation products resulting from the peptide components were not determined.